Comparative Pharmacology
Head-to-head clinical analysis: REGORAFENIB versus RETEVMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REGORAFENIB versus RETEVMO.
REGORAFENIB vs RETEVMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Regorafenib is a multikinase inhibitor that targets various angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, RAF). It inhibits tumor angiogenesis, growth, and metastasis.
RETEVMO (selpercatinib) is a potent and selective RET kinase inhibitor. It inhibits wild-type RET and multiple RET fusions (e.g., KIF5B-RET, CCDC6-RET) and mutations (e.g., M918T, C634W, V804M/L/E) by binding to the ATP-binding site of RET, blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT, thereby inhibiting tumor cell proliferation.
160 mg orally once daily on days 1-21 of a 28-day cycle until disease progression or unacceptable toxicity.
160 mg orally twice daily
None Documented
None Documented
Clinical Note
moderateRegorafenib + Digoxin
"Regorafenib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateRegorafenib + Digitoxin
"Regorafenib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateRegorafenib + Deslanoside
"Regorafenib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateRegorafenib + Acetyldigitoxin
"Regorafenib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life is 14–28 hours (mean approximately 20 hours), supporting twice-daily dosing with a 3-weeks-on/1-week-off schedule to allow washout and reduce toxicity accumulation.
18 hours (terminal elimination half-life) supporting twice-daily dosing; steady-state reached within ~3 days.
Primarily fecal (approximately 71% of the radiolabeled dose) with renal excretion accounting for 19% (mostly as metabolites). Unchanged regorafenib is minimal in urine.
Primarily biliary/fecal (approximately 75% of administered dose recovered in feces as unchanged drug and metabolites); renal elimination accounts for <10% (mostly metabolites).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor